Recent investigations suggest that serum FlnA levels can serve as an innovative biomarker for stratified PCa screening, surpassing PSA in screening efficacy (Panigrahi et al., 2019; Leitão et al., 2022; Mahaveer Chand et al., 2024). This evidence concerns the gene FLNA and posterior cortical atrophy.